Two-way immunogenicity testing on existing clinical trial sera to immunogenicity superiority of a new vaccine strain versus the prototype strain
Active Awarded Last action
- Contract number
- 75A50126F61020
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $493,470
Award facts
- Contract value 100% obligated
- $493,470.00 Current and potential, with all options
- Completion date 98% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27701, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a firm fixed-price delivery order valued at $493,470 to GlaxoSmithKline, LLC on March 13, 2026, with completion scheduled for October 29, 2026. The contract calls for two-way immunogenicity testing on existing clinical trial sera to establish immunogenicity superiority of a new vaccine strain versus the prototype strain. The work will be performed in Durham, North Carolina. No set-aside designation was applied to this contract award.
GlaxoSmithKline, a foreign-owned pharmaceutical company headquartered in Durham, North Carolina, is a significant federal contractor specializing in vaccines and medical countermeasures. The company maintains extensive relationships with federal agencies including the Centers for Disease Control and Prevention, Department of Defense, and Department of Veterans Affairs, with prior contract values ranging from several thousand dollars to contracts with ceilings exceeding $3.9 billion. This delivery order aligns with the company's core competency in vaccine development and immunogenicity assessment, supporting the federal government's preparedness and public health initiatives.
Quick answers
Who was awarded contract 75A50126F61020?
75A50126F61020 was awarded to Glaxosmithkline, LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on March 13, 2026.
How much is contract 75A50126F61020 worth?
The government has obligated $493,470 on 75A50126F61020.
Is contract 75A50126F61020 an order under another contract?
Yes. 75A50126F61020 is a delivery order under 75A50122D00002, an indefinite delivery contract.
Was contract 75A50126F61020 competed?
The extent of competition for 75A50126F61020 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award